Trump’s first 100 days tout US-bound pharma investments amid tariff worries
Pharma companies are looking to shore up manufacturing operations in the US to counter international tariffs, but are also bracing…
Trump Tariffs
-
-
Impending US tariffs signal uncertain future for global pharma, says GlobalData
In early 2025, US President Donald Trump mentioned the possibility of potential tariffs on foreign-made pharmaceuticals. This threat was raised…
-
US tariffs likely to disrupt drug development costs and prices, says GlobalData
While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the…
-
AstraZeneca CEO calls for increased European investment in pharma
AstraZeneca CEO Pascal Soriot has urged European governments to increase investment in pharmaceutical innovation, warning of a growing imbalance between…
-
Small biotechs shoulder the burdens of an uncertain biopharma sector
Recent US tariffs and federal funding cuts mean a heightened uncertainty for biopharma investors, and small biotechs are set to…
-
Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds
The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
-
MSD’s Gardasil sales slide further due to China constraints
A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus…
-
Thermo Fisher counters tariffs with $2bn investment into US manufacturing
Thermo Fisher has outlaid $2bn to expand manufacturing and development in the US, joining the long list of companies directing…
-
Pharma companies in Europe push for US-level drug prices
Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US, as reported by…
-
Roche announces $50bn US investment in pharma and diagnostics
Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the next five years to bolster…
